Results 201 to 210 of about 373,948 (350)

Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens   +14 more
wiley   +1 more source

The effect of adding dexamethasone to adductor block and IPACK block on acute postoperative, rebound, and chronic pain following knee arthroplasty-1-year follow-up. [PDF]

open access: yesFront Med (Lausanne)
Sreckovic S   +8 more
europepmc   +1 more source

Organ toxicities associated with diet‐induced obesity in rats: Investigation of changes in activities selected enzymes

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
Abstract Obesity stands out as one of the most significant health problems in the modern world. The prevalence of high‐calorie diets (HCDs) globally exacerbates this condition. Throughout history, plants and plant‐derived food products have been utilized for medicinal purposes, demonstrating their efficacy in the treatment and prevention of various ...
Bedia Bati
wiley   +1 more source

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, Volume 91, Issue 5, Page 1306-1321, May 2025.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy